Reshaping the HIV treatment and prevention landscape

Maintaining HIV leadership beyond Dolutegravir Integrase inhibitor-based LA regimens deliver new levels of convenience gsk 2021-2024 Cabenuva (CAB + RPV) for treatment - - 1st LA regimen launched in US and EU with more planned Cabotegravir for prevention (PrEP) - US approval expected Q1 2022 2025-2027 1st self-administered LA regimen for treatment — - CAB + MI-937 - - CAB + N6LS Cabotegravir for prevention (PrEP) - Ultra long-acting CAB for PrEP 2028+ Ultra long-acting >Q3M for treatment - CAB + Capsid - CAB + N6LS - CAB + NRTTI 80

View entire presentation